bioAffinity Technologies, Inc. - SIC # 8081 -

Ticker Exchange SIC # Website Latest Ticker
BIAF Nasdaq 8081 bioaffinitytech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for bioAffinity Technologies, Inc.

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 - Oct 15th, 2026 6:00 am
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 - Oct 13th, 2026 6:00 am
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Oct 9th, 2026 10:30 am
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Oct 9th, 2026 9:37 am
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Oct 8th, 2026 11:30 am
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Oct 8th, 2026 10:07 am
bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test - Oct 8th, 2026 8:34 am
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm - Oct 8th, 2026 6:00 am
bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 - Oct 6th, 2026 7:19 am
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL - Sep 30th, 2026 6:00 am
bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection - Sep 28th, 2026 3:17 am
bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference - Sep 22nd, 2026 8:41 am
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference - Sep 22nd, 2026 6:00 am
bioAffinity Technologies Secures Hong Kong Patent for CyPath Lung Cancer Diagnostic - Sep 17th, 2026 8:21 am
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic - Sep 17th, 2026 6:00 am
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Sep 9th, 2026 6:00 am
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? - Sep 5th, 2026 12:13 am
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Sep 3rd, 2026 2:30 pm
bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update - Sep 3rd, 2026 6:21 am
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance - Sep 1st, 2026 9:03 am